chevron_leftBack
As of 13 June 2026, Definium Therapeutics, Inc. has a market cap of $2.04B USD, ranking #6927 globally and #1684 in the United States.
It ranks #554 in the Healthcare sector, and #218 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$2.04BUSD
Enterprise Value
$1.67BUSD
EBITDA (TTM)
-$166.28MUSD
Net Income (TTM)
-$183.79MUSD
PB Ratio
6.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Robert Barrow
open_in_new
Employees
106
Website
definiumtx.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -3.7% | -11% | 15% | 22% | 59% | 222% |
News
Loading...
DFTX Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
DFTX
ISIN: CA24477V1058
Shares Out.:
Shares Outstanding:
109.067M1
Shares Float:
104.893M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
20.49 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
37K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
27K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
18K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
13K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
7K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
6K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
16K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
14K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
13K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
9K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
5K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
5K%
80.96B GBP
|
14.6
|
chevron_leftBack